Injectable Tirzepatide Under $250/Month: Who Actually Delivers at That Price

Tirzepatide — the dual GLP-1/GIP agonist behind Mounjaro and Zepbound — has become the molecule patients ask about most. The clinical data shows it produces greater average weight loss than semaglutide in head-to-head comparisons, with some studies reporting average weight loss of 20% or more of body weight. That performance comes at a premium: compounded tirzepatide generally costs $25 to $100 more per month than compounded semaglutide at equivalent dose levels.

But the gap is narrowing. Competition among compounding providers and stabilizing API costs have pushed starting prices for injectable compounded tirzepatide below $250/month at several providers — a threshold that makes the dual-agonist option accessible to patients who previously defaulted to semaglutide on price alone.

The Tirzepatide Premium Explained

Tirzepatide costs more to compound than semaglutide for straightforward reasons:

• API cost: Tirzepatide API (active pharmaceutical ingredient) is currently more expensive per milligram than semaglutide API, reflecting newer manufacturing processes and fewer registered suppliers
• Higher dose ranges: Tirzepatide's therapeutic dose range (2.5 mg to 15 mg/week) is higher by milligram weight than semaglutide's range (0.25 mg to 2.4 mg/week), meaning more API per vial at equivalent treatment stages
• Market positioning: Providers position tirzepatide as the "premium" option, commanding higher margins even when the API cost difference doesn't fully justify the patient-facing price gap

The Sub-$250 Tirzepatide Market

Providers offering injectable compounded tirzepatide at starting prices under $250/month have expanded significantly in 2026. The competitive landscape includes both dedicated tirzepatide programs and providers that offer semaglutide and tirzepatide side-by-side with molecule-specific pricing.

Key observations about sub-$250 tirzepatide pricing:

• Starting dose vs. maintenance dose gap is wider: Because tirzepatide's dose range is broader, the price difference between starting dose (2.5 mg) and maintenance dose (10–15 mg) is larger than the equivalent semaglutide gap. A provider starting at $199/month may charge $399 or more at the 15 mg dose level.
• Oral tirzepatide is sometimes cheaper: Some providers offer compounded oral tirzepatide (tablets or troches) at prices below their injectable tirzepatide rates, because oral formulations use different compounding processes and the lower bioavailability is offset by competitive pricing pressure in the newer oral format market.
• Combination programs exist: Some providers offer "start on semaglutide, switch to tirzepatide" programs where you begin at semaglutide pricing and upgrade to tirzepatide after the initial titration, potentially at a discounted tirzepatide rate as a retention incentive.

Semaglutide vs. Tirzepatide: Is the Premium Worth It?

This is the question every cost-conscious patient asks. The answer depends on clinical factors, financial factors, and personal priorities:

Clinical Case for Tirzepatide

• Clinical trials show approximately 5 to 7 percentage points more average weight loss with tirzepatide vs. semaglutide at comparable treatment durations
• Dual GLP-1/GIP mechanism may provide additional benefits for insulin sensitivity and metabolic health beyond what GLP-1-only medications offer
• Some patients who plateau on semaglutide respond to tirzepatide — the different mechanism profile can restart progress

Financial Case for Semaglutide

• $25 to $100/month less at every dose tier translates to $300 to $1,200 in annual savings
• Longer market history means more providers, more competition, and more pricing pressure at every tier
• If semaglutide achieves your weight loss and health goals, the additional efficacy of tirzepatide has no marginal value to you

Total Cost Projection: 12 Months of Tirzepatide

Using representative pricing for a patient who titrates from 2.5 mg to 10 mg over 16 weeks, then maintains at 10 mg:

• Months 1–2 (2.5 mg): ~$199/month = $398
• Months 3–4 (5.0 mg): ~$249/month = $498
• Months 5–12 (10 mg): ~$349/month = $2,792
• 12-month estimated total: ~$3,688

Compare to brand-name Zepbound without insurance at ~$1,050/month (~$12,600/year). Compounded tirzepatide represents approximately 70% savings over brand-name, even at higher dose tiers.

Questions to Ask Tirzepatide Providers

• "Is tirzepatide pricing the same structure as your semaglutide pricing, or is it a separate tier?"
• "What is the price at the 10 mg and 15 mg dose levels?"
• "Can I switch from semaglutide to tirzepatide mid-treatment without re-enrolling?"
• "Does the oral tirzepatide option cost more or less than injectable at equivalent doses?"
• "Which pharmacy compounds your tirzepatide, and is it the same pharmacy as your semaglutide?"

Frequently Asked Questions